EICHOR
● Recruiting
Phase 2 Study of Fingolimod in Lung Cancers
Condition: Non Small Cell Lung Cancer · Small-cell Lung Cancer · Sponsor: Medical University of South Carolina
About this study
This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) who have progressed on chemo-immunotherapy. The study design will be a 6 patient safety lead-in with 2 cohorts of patients for efficacy analysis where fingolimod 0.5 mg will be taken orally once daily.
This description comes directly from the study's public registry record.
Talk to the study team
HCC Clinical Trials Office · 843-792-9321 · hcc-clinical-trials@musc.edu
Always discuss trial participation with your own doctor first.
Locations (1)
| Hollings Cancer Center at Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06424067